Latest news with #pathology
National Post
a day ago
- Health
- National Post
Canucks: B.C. cancer initiative hits home for Kirk and Genevieve McLean
Article content Funding addresses the following foundation goals: Article content • Renewed pathology laboratory at VGH to use the power of robotics and AI (Artificial Intelligence) to decrease diagnostic turnaround time and facilitate more accurate diagnosis. Article content • State-of-the-art operating rooms and surgical tools. In April, VGH became the first hospital in Canada to conduct a surgical procedure by using a spine robot. In May, VGH opened the province's first in-patient clinical trials unit. Article content Genevieve was diagnosed with leukemia as a child, and nine years later at the age of 24 there was a relapse. She received a life-saving blood transplant from her brother at VGH. However, in 2017, Genevieve faced another cancer battle. A six-by-five centimetre tumour was discovered in her adrenal gland and successfully removed. Article content She remains cancer free today and is beyond grateful. Article content 'It for sure changes you, because the little things now don't matter as much after going through that,' said Genevieve. 'It changes your perspective as the years go by because you realize how lucky you are. There's the cancer portion and the treatments and a lot of parts in your body are affected. Article content Article content 'Cancer doesn't just happen, it goes much further along and is always evolving. You get it and you think you're not going to graduate or get married and worry about the future. That's where it changed me. I was fortunate to meet Kirk's parents and it was very similar because faith is a big part of us. And so is being happy day by day because life isn't guaranteed.' Article content Cancer doesn't play favourites. Genevieve played sports in high school and was modelling when struck by the cancer relapse. There was no family history of cancer. She had been in New York and Italy and then returned home, and wham, it hit her again. And when it struck for a third time, her mettle was tested. Was this like baseball, three strikes and she's out? Article content 'I had lower-back pain, but I played sports growing up and thought it was just from working out, but Kirk told me it was ridiculous. Your back shouldn't be hurting all the time,' recalled Genevieve. 'I had such pain before, that this was nothing in the grand scheme of things, and I just put it (examination) off. Article content
Yahoo
14-07-2025
- Business
- Yahoo
Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology
LONDON & BOSTON & STRASBOURG, France, July 14, 2025--(BUSINESS WIRE)--Summit Partners today announced a growth investment in Dreampath Diagnostics, a leading healthcare technology company focused on digitizing workflows in anatomical pathology laboratories. The investment will support the company's plans to accelerate global growth, scale operations and expand its commercial reach and product portfolio. Founded in 2012, Dreampath offers a patented suite of traceability solutions and consumables designed to automate and digitally transform the archiving and retrieval of tissue samples in pathology labs. Today, the company manages more than 250 million samples across over 500 labs in nearly 40 countries, serving a broad range of healthcare organizations, from hospitals and research institutions to commercial laboratories and cancer centers. "Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval," said Pablo Jordan, CEO and co-founder of Dreampath Diagnostics. "Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We're proud to partner with Summit to help us scale our impact and reach more patients around the world." Dreampath's integrated platform is protected by more than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to help eliminate the risk of patient sample loss. The company's technology is tailored to specific stages of the pathology process and works with Dreampath's proprietary software and consumables. This closed-loop system helps labs archive and retrieve tissue samples with speed and precision, with a focus on improving sample traceability while reducing manual errors, retrieval times and operational burden. Customers using the system have reported meaningful positive results, noting an 83% reduction in time spent archiving tissue samples. Dreampath has grown profitably and rapidly at a CAGR of more than 50% in recent years, driven by strong demand for its platform across the U.S., EMEA and other global markets. Dreampath's customers include many of the world's foremost cancer centers, as well as some of the largest and most sophisticated commercial laboratories in operation today. "Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven't meaningfully evolved in decades," said Thomas Tarnowski, Managing Director at Summit Partners. "Dreampath's platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernization of pathology infrastructure on a global scale." "We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics," added Jono Pagden, Principal at Summit Partners. "In our view, the company's first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We're proud to be their first institutional partner and excited to support the team in scaling their impact globally." Both Thomas Tarnowski and Jono Pagden have joined the Dreampath Board of Directors. Dreampath is headquartered in Strasbourg, France with a U.S. commercial office in New York. Financial terms of the transaction were not disclosed. About Dreampath Diagnostics Dreampath Diagnostics is a global leader of digital sample management systems for anatomical pathology laboratories. The company's patented solutions combine purpose-built scanners, software and consumables to enable automated and error-free archiving and rapid retrieval of tissue samples, helping labs accelerate diagnostics, improve accuracy, and compliance. Dreampath's systems are used in leading labs and institutions across nearly 40 countries. For more information, please visit About Summit Partners Summit Partners is a leading growth-focused investment firm. Summit invests across growth sectors of the economy and, since the firm's founding in 1984, has invested in more than 550 companies in technology, healthcare and other growth industries. These companies have completed more than 175 public equity offerings, and more than 250 have been acquired through strategic mergers and sales. Notable investments in healthcare and life sciences include Advance Medical, CluePoints, Healthline Media, LifeStance Health, VaxCare and Viroclinics. Summit maintains offices in North America and Europe and seeks to invest in category-leading, profitable growth companies worldwide. For more information, please visit or follow on LinkedIn. View source version on Contacts Media Contact:Susan Barrsbarr@
Yahoo
14-07-2025
- Business
- Yahoo
Summit Partners Announces Growth Investment in Dreampath Diagnostics to Accelerate Digital Transformation in Anatomical Pathology
LONDON & BOSTON & STRASBOURG, France, July 14, 2025--(BUSINESS WIRE)--Summit Partners today announced a growth investment in Dreampath Diagnostics, a leading healthcare technology company focused on digitizing workflows in anatomical pathology laboratories. The investment will support the company's plans to accelerate global growth, scale operations and expand its commercial reach and product portfolio. Founded in 2012, Dreampath offers a patented suite of traceability solutions and consumables designed to automate and digitally transform the archiving and retrieval of tissue samples in pathology labs. Today, the company manages more than 250 million samples across over 500 labs in nearly 40 countries, serving a broad range of healthcare organizations, from hospitals and research institutions to commercial laboratories and cancer centers. "Pathology labs are a critical part of the global healthcare ecosystem, yet many still rely on manual, error-prone processes for sample archiving and retrieval," said Pablo Jordan, CEO and co-founder of Dreampath Diagnostics. "Our mission is to improve the efficiency and accuracy of these workflows through automation and digital traceability, allowing labs to provide patients with faster and safer diagnostics. We're proud to partner with Summit to help us scale our impact and reach more patients around the world." Dreampath's integrated platform is protected by more than 80 patents worldwide and is designed to automate, simplify and streamline lab workflows to help eliminate the risk of patient sample loss. The company's technology is tailored to specific stages of the pathology process and works with Dreampath's proprietary software and consumables. This closed-loop system helps labs archive and retrieve tissue samples with speed and precision, with a focus on improving sample traceability while reducing manual errors, retrieval times and operational burden. Customers using the system have reported meaningful positive results, noting an 83% reduction in time spent archiving tissue samples. Dreampath has grown profitably and rapidly at a CAGR of more than 50% in recent years, driven by strong demand for its platform across the U.S., EMEA and other global markets. Dreampath's customers include many of the world's foremost cancer centers, as well as some of the largest and most sophisticated commercial laboratories in operation today. "Pathology labs are navigating growing volumes, staffing shortages and increasing demands for precision, all while working with systems that haven't meaningfully evolved in decades," said Thomas Tarnowski, Managing Director at Summit Partners. "Dreampath's platform is designed to address a key bottleneck in the pathology workflow. By enabling fast and traceable access to tissue samples, the company is supporting more consistent lab operations and helping improve the quality of patient care. We believe Dreampath is well-positioned to lead the modernization of pathology infrastructure on a global scale." "We were drawn to Dreampath because of their clear leadership in a fast-growing and increasingly essential segment of lab diagnostics," added Jono Pagden, Principal at Summit Partners. "In our view, the company's first-mover advantage, consistent focus on quality and strong customer adoption have helped Dreampath establish a strong reputation as a trusted provider in digital archiving. We're proud to be their first institutional partner and excited to support the team in scaling their impact globally." Both Thomas Tarnowski and Jono Pagden have joined the Dreampath Board of Directors. Dreampath is headquartered in Strasbourg, France with a U.S. commercial office in New York. Financial terms of the transaction were not disclosed. About Dreampath Diagnostics Dreampath Diagnostics is a global leader of digital sample management systems for anatomical pathology laboratories. The company's patented solutions combine purpose-built scanners, software and consumables to enable automated and error-free archiving and rapid retrieval of tissue samples, helping labs accelerate diagnostics, improve accuracy, and compliance. Dreampath's systems are used in leading labs and institutions across nearly 40 countries. For more information, please visit About Summit Partners Summit Partners is a leading growth-focused investment firm. Summit invests across growth sectors of the economy and, since the firm's founding in 1984, has invested in more than 550 companies in technology, healthcare and other growth industries. These companies have completed more than 175 public equity offerings, and more than 250 have been acquired through strategic mergers and sales. Notable investments in healthcare and life sciences include Advance Medical, CluePoints, Healthline Media, LifeStance Health, VaxCare and Viroclinics. Summit maintains offices in North America and Europe and seeks to invest in category-leading, profitable growth companies worldwide. For more information, please visit or follow on LinkedIn. View source version on Contacts Media Contact:Susan Barrsbarr@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Health Line
10-07-2025
- Health
- Health Line
Pathologists and Pathology: All About These Specialists
A pathologist is a doctor who looks at bodies and body tissues. They run tests in a lab and often work in tandem with other medical specialists to diagnose medical conditions. Pathology is broken up into numerous specialties. Pathology is the study of diseases, their causes, their progression, and their effect on the human body. The name comes from the Greek word 'pathología,' which means 'suffering.' In the context of pathology, 'disease' is any deviation from a set of observable characteristics of an individual resulting from the interaction of their genes with their environment. This deviation is quantified and measured via symptoms reported by the person experiencing them, as well as signs measured through tests by a pathologist. The cause of the disease is referred to as its etiology. Disease develops through a series of chemical or cellular reactions, which a pathologist studies and investigates. Learn more about the role of a pathologist below. What does a pathologist do? A pathologist analyzes tissues, cells, and bodily fluids. They are an important part of a medical professional team, often tasked with answering important questions about disease, such as: 'What is it?' (a diagnosis) 'How is it going to behave?' (a prognosis) 'How should it be treated?' (treatment strategy) Pathologists make this determination by looking at the cellular, chemical, and mechanical behavior of body and its tissues, using their observations, the results of tests they perform, and newly developed computing technologies. These medical doctors specialize in looking at human tissue, blood, urine, and other bodily fluids under a microscope. Oftentimes, they work in the background without speaking to patients. According to a paper published in 2020, the role of pathologists in medical research and treatment is growing as the human genome is deciphered, and as complex interactions of cellular biochemistry are refined and the risk of disease is more accurately calculated. What are the types of pathology There are several sub-specialties of pathology, and these medical specialists usually focus on one to several types. Blood banking and transfusion: This type of pathologist maintains an adequate blood supply, blood donor and recipient safety, and appropriate blood use at a medical facility. They direct the preparation and safe use of specially prepared blood components, including red blood cells, white blood cells, platelets and plasma constituents, and bone marrow or stem cells for transplantation. Clinical pathology: A clinical, or chemical, pathologist specializes in the biochemistry of the human body to understand disease diagnosis and progression. They monitor substances in bodily fluids like blood and urine to assess changes in someone's body. Clinical informatics: These specialists evaluate data, health trends, and communication systems and use this information to improve medical processes that will allow for better patient outcomes. Think of them as the quality control of pathology. Cytopathology: This type of pathology is the study of individual cells of the body. The human body is made up of millions of cells that can be looked at under the microscope to help diagnose medical conditions. It's often used to diagnose cancer, other conditions of the respiratory, urinary, and gastrointestinal tracts, and thyroid gland, salivary glands, and lymph nodes. Dermatopathology: This discipline specializes in human skin diseases. It involves the microscopic examination, description, and interpretation of biopsy specimens. Dermatopathologists often have training in dermatology. Forensic pathology: This is the study of tissue or bodily fluid in a person after their violent, sudden, and unexpected death. Forensic pathologists are sometimes also medical examiners or coroners, performing autopsies for a government law enforcement agency. Their job is to identify the cause and manner in which someone died. Hematopathology: A hematologist studies conditions specific to blood cells, blood clotting, bone marrow, and lymph nodes. They use blood samples to diagnose conditions like anemia and blood cancers. Medical microbiology: This discipline specializes in infectious organisms and diseases. They take part in the work to prevent, diagnose, and treat conditions that result from microorganisms. Molecular genetic pathology: This type of specialist expert investigates gene structure, function, and mutations. They use laboratory testing to help diagnose, treat, and provide a prognosis for people with genetic disorders, infectious diseases, and human development. They also help determine the risk of genetic disorders. Neuropathology: Neuropathologists study conditions that affect the nervous system and skeletal muscles. They often work with neurologists and neurosurgeons to diagnose neurological diseases, and also analyze tissue samples following death to study dementia, assess trauma, and evaluate genetic conditions. Surgical pathology: This is the study of the tissues removed during surgery —such as a tumor—to help diagnose a disease and determine a treatment plan. This can sometimes occur while a surgery is ongoing, and can inform surgeons on how to proceed. Pediatric pathology: This type of pathology involves the research of conditions that occur during fetal growth, infancy, and child development. Pediatric pathologists investigate diseases in children up to 18 years of age. How much education and training is required of pathologists? In order to become a pathologist in the United States, a medical professional starts with a four-year undergraduate degree, often in chemistry or biology. Next is a four-year doctorate degree in medicine, either for a doctor of medicine (MD) or doctor of osteopathic medicine (DO). This is followed by a medical residence in a medical facility, which for pathology usually lasts for three years. Combined residencies in both anatomical and clinical pathology can take four years or longer. In all, the process can take 11 years or longer.
ABC News
14-06-2025
- Health
- ABC News
Body parts kept in Hobart pathology museum
A university pathology museum has in its collection specimens possibly retained from coronial autopsies without consent.
